These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 18055335)

  • 41. Treatment of the 5q- syndrome.
    Fenaux P; Kelaidi C
    Hematology Am Soc Hematol Educ Program; 2006; ():192-8. PubMed ID: 17124060
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.
    Raza A; Reeves JA; Feldman EJ; Dewald GW; Bennett JM; Deeg HJ; Dreisbach L; Schiffer CA; Stone RM; Greenberg PL; Curtin PT; Klimek VM; Shammo JM; Thomas D; Knight RD; Schmidt M; Wride K; Zeldis JB; List AF
    Blood; 2008 Jan; 111(1):86-93. PubMed ID: 17893227
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.
    Heise C; Carter T; Schafer P; Chopra R
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1663-72. PubMed ID: 20942636
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide.
    Kurtin SE; List AF
    Clin Lymphoma Myeloma; 2009 Jun; 9(3):E10-3. PubMed ID: 19525184
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes.
    Voutsadakis IA; Cairoli A
    Leuk Lymphoma; 2012 May; 53(5):779-88. PubMed ID: 21955212
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: Is it any good?
    Sekeres MA; List A
    Curr Hematol Malig Rep; 2006 Mar; 1(1):16-9. PubMed ID: 20425326
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more?
    Komrokji RS; Lancet JE; List AF
    Curr Hematol Malig Rep; 2010 Jan; 5(1):9-14. PubMed ID: 20425391
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evolution of severe (transfusion-dependent) anaemia in myelodysplastic syndromes with 5q deletion is characterized by a macrophage-associated failure of the eythropoietic niche.
    Buesche G; Teoman H; Schneider RK; Ribezzo F; Ebert BL; Giagounidis A; Göhring G; Schlegelberger B; Bock O; Ganser A; Aul C; Germing U; Kreipe H
    Br J Haematol; 2022 Jul; 198(1):114-130. PubMed ID: 35362549
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion.
    Oliva EN; Cuzzola M; Nobile F; Ronco F; D'Errigo MG; Laganà C; Morabito F; Galimberti S; Cortelezzi A; Aloe Spiriti MA; Specchia G; Poloni A; Breccia M; Ghio R; Finelli C; Iacopino P; Alimena G; Latagliata R
    Eur J Haematol; 2010 Sep; 85(3):231-5. PubMed ID: 20491881
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?
    Vozella F; Latagliata R; Carmosino I; Volpicelli P; Montagna C; Romano A; Roberto A; Finsinger P; Mancini M; Breccia M; Oliva E; Oliva E
    Hematol Oncol; 2015 Mar; 33(1):48-51. PubMed ID: 25950027
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome.
    Komrokji RS; Lancet JE; Swern AS; Chen N; Paleveda J; Lush R; Saba HI; List AF
    Blood; 2012 Oct; 120(17):3419-24. PubMed ID: 22936658
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide.
    Merkerova MD; Krejcik Z; Belickova M; Hrustincova A; Klema J; Stara E; Zemanova Z; Michalova K; Cermak J; Jonasova A
    Eur J Haematol; 2015 Jul; 95(1):35-43. PubMed ID: 25287904
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of lenalidomide in the management of myelodysplasia with del 5q.
    Kelaidi C; Eclache V; Fenaux P
    Br J Haematol; 2008 Feb; 140(3):267-78. PubMed ID: 18217896
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lenalidomide in myelodysplastic syndrome and multiple myeloma.
    Shah SR; Tran TM
    Drugs; 2007; 67(13):1869-81. PubMed ID: 17722955
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Aberrant expression of the microRNA cluster in 14q32 is associated with del(5q) myelodysplastic syndrome and lenalidomide treatment.
    Krejčík Z; Beličková M; Hruštincová A; Kléma J; Zemanová Z; Michalová K; Čermák J; Jonášová A; Dostálová Merkerová M
    Cancer Genet; 2015 Apr; 208(4):156-61. PubMed ID: 25883014
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis.
    Rojas SM; Díez-Campelo M; Luño E; Cabrero M; Pedro C; Calabuig M; Nomdedeu B; Cedena T; Arrizabalaga B; García M; Cerveró C; Collado R; Azaceta G; Ardanaz MT; Muñoz JA; Xicoy B; Rodríguez MJ; Bargay J; Morell MJ; Simiele A; del Cañizo C
    Leuk Res; 2014 Mar; 38(3):304-9. PubMed ID: 24333115
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.
    List AF; Bennett JM; Sekeres MA; Skikne B; Fu T; Shammo JM; Nimer SD; Knight RD; Giagounidis A;
    Leukemia; 2014 May; 28(5):1033-40. PubMed ID: 24150217
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.
    Haferlach C; Bacher U; Tiu R; Maciejewski JP; List A
    Cancer Genet Cytogenet; 2008 Dec; 187(2):101-11. PubMed ID: 19027491
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of Lenalidomide Treatment on Overall Survival in Patients With Lower-Risk, Transfusion-Dependent Myelodysplastic Syndromes.
    Santini V; Giagounidis A; Pelligra CG; Franco-Villalobos C; Tang D; Morison J; Beach CL; Hu A; Platzbecker U; Fenaux P
    Clin Lymphoma Myeloma Leuk; 2022 Sep; 22(9):e874-e883. PubMed ID: 35710702
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.
    Sibon D; Cannas G; Baracco F; Prebet T; Vey N; Banos A; Besson C; Corm S; Blanc M; Slama B; Perrier H; Fenaux P; Wattel E;
    Br J Haematol; 2012 Mar; 156(5):619-25. PubMed ID: 22211483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.